Pacific Biosciences of California, Inc. is a premium stock of StocksGuide. Please log in to activate an alert for Pacific Biosciences of California, Inc..
Register for Free
Please register for free to add Pacific Biosciences of California, Inc. to your portfolio.
Pacific Biosciences of California, Inc. Stock News
Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term...
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Nixon - Canaccord Mason Carrico - Stephens Dan Bre...
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million p...
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory
BOSTON , Oct. 30, 2024 /PRNewswire/ -- Volta Labs™, a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the partnership between Volta Labs and PacBio. Volta Labs is partnering with PacBio to offer walk-away automation for PacBio library prep, enabling labs to scale sample prep for sequencing.
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.